$35.50
7.82[28.25%]
At close: May 20
$35.50
0[0.00%]
After Hours: 7:59PM EDT
Dyne Therapeutics
(NASDAQ:DYN)Dyne Therapeutics Stock (NASDAQ:DYN), Analyst Ratings, Price Targets, Predictions
Dyne Therapeutics Inc has a consensus price target of $39.3, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Jefferies, HC Wainwright & Co., and Chardan Capital on May 20, 2024, May 20, 2024, and May 6, 2024. With an average price target of $40.33 between Jefferies, HC Wainwright & Co., and Chardan Capital, there's an implied 13.62% upside for Dyne Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
HC Wainwright & Co.
Chardan Capital
Oppenheimer
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Dyne Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2024 | Buy Now | 18.31% | Jefferies | — | $36 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 35.21% | HC Wainwright & Co. | Andrew Fein | $46 → $48 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | -12.68% | Chardan Capital | Keay Nakae | $31 → $31 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 32.39% | Oppenheimer | Francois Brisebois | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 1.41% | HC Wainwright & Co. | Andrew Fein | → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 12.68% | Morgan Stanley | Michael Ulz | → $40 | Initiates | → Overweight | Get Alert |
| 03/26/2024 | Buy Now | 32.39% | Oppenheimer | Francois Brisebois | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | -12.68% | Chardan Capital | Keay Nakae | $20 → $31 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | 4.23% | Guggenheim | Debjit Chattopadhyay | $33 → $37 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 1.41% | HC Wainwright & Co. | Andrew Fein | → $36 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 15.49% | Stifel | Paul Matteis | $35 → $41 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | -18.31% | Piper Sandler | Edward Tenthoff | $27 → $29 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 32.39% | Oppenheimer | Francois Brisebois | $44 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 1.41% | HC Wainwright & Co. | Andrew Fein | → $36 | Initiates | → Buy | Get Alert |
| 01/04/2024 | Buy Now | 57.75% | Raymond James | Steven Seedhouse | $27 → $56 | Maintains | Strong Buy | Get Alert |
| 08/09/2023 | Buy Now | -38.03% | JP Morgan | Tessa Romero | $20 → $22 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -43.66% | Chardan Capital | Keay Nakae | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2023 | Buy Now | -43.66% | Chardan Capital | Keay Nakae | $17 → $20 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | -23.94% | Raymond James | Steven Seedhouse | $16 → $27 | Upgrade | Outperform → Strong Buy | Get Alert |
| 02/15/2023 | Buy Now | -4.23% | Oppenheimer | Francois Brisebois | → $34 | Initiates | → Outperform | Get Alert |
| 01/26/2023 | Buy Now | -7.04% | Guggenheim | Debjit Chattopadhyay | → $33 | Initiates | → Buy | Get Alert |
| 11/29/2022 | Buy Now | -49.3% | JP Morgan | Tessa Romero | $24 → $18 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | -54.93% | Raymond James | Steven Seedhouse | $15 → $16 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | -52.11% | Chardan Capital | Keay Nakae | → $17 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | -57.75% | Raymond James | Steven Seedhouse | → $15 | Initiates | → Outperform | Get Alert |
| 05/23/2022 | Buy Now | -66.2% | Piper Sandler | Edward Tenthoff | $16 → $12 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Dyne Therapeutics (DYN)?
The latest price target for Dyne Therapeutics (NASDAQ: DYN) was reported by Jefferies on May 20, 2024. The analyst firm set a price target for $42.00 expecting DYN to rise to within 12 months (a possible 18.31% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dyne Therapeutics (DYN)?
The latest analyst rating for Dyne Therapeutics (NASDAQ: DYN) was provided by Jefferies, and Dyne Therapeutics maintained their buy rating.
When was the last upgrade for Dyne Therapeutics (DYN)?
The last upgrade for Dyne Therapeutics Inc happened on February 27, 2023 when Raymond James raised their price target to $27. Raymond James previously had an outperform for Dyne Therapeutics Inc.
When was the last downgrade for Dyne Therapeutics (DYN)?
There is no last downgrade for Dyne Therapeutics.
When is the next analyst rating going to be posted or updated for Dyne Therapeutics (DYN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on May 20, 2024 so you should expect the next rating to be made available sometime around May 20, 2025.
Is the Analyst Rating Dyne Therapeutics (DYN) correct?
While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a maintained with a price target of $36.00 to $42.00. The current price Dyne Therapeutics (DYN) is trading at is $35.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.